Equities researchers at Wedbush decreased their FY2025 earnings estimates for shares of Replimune Group in a research report ...

Shares of NASDAQ REPL opened at $13.75 on Wednesday. Replimune Group has a 1 year low of $4.92 and a 1 year high of $17.00. The company has a market capitalization of $940.78 million, a price-to ...

Barclays analyst Peter Lawson maintained a Buy rating on Replimune Group (REPL – Research Report) today and set a price target of $17.00. The ...

Leerink analyst Jonathan Chang raised the firm’s price target on Replimune (REPL) to $21 from $18 to reflect an increased probability of ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Replimune Group (REPL) has disclosed a new risk, in the Share Price & Shareholder Rights category. Replimune Group faces a range of material risks ...

Short interest in Replimune Group Inc (NASDAQ:REPL) increased during the last reporting period, rising from 5.93M to 6.61M. This put 11.84% of the company's publicly available shares short.

Replimune (REPL) Group announced that the first patients have been enrolled in studies evaluating RP2 in two different settings: checkpoint naive metastatic uveal melanoma; and second-line ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...